image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Reach - Shares bounce 22% after results

April 2024

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • RCH
  • Price:
  • 74p
The shares bounced following results slightly ahead of expectations, aided by an improving Q4 and a “robust” start to January and February. Revenues declined 5.4% with the EBIT impact minus 9%. In print, revenues fell 3.5% although advertising outperformed long-term declining trends. Within Digital, Facebook’s newsfeed switch off, google algorithm changes and hard macro conditions lowered revenues by 15% to £127.4m due to page views and lower open market yields both declining a quarter but that’s the worst of it. Reach’s investment in the data-driven segment has been rewarded with an increased contribution to 43% of divisional sales from 38% in FY’22. Crucially, Reach is squeezing far more from fewer eyeballs with revenue per thou ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author